Replies to post #105011 on Innovation Pharmaceuticals Inc (IPIX)

[frrol]

It's encouraging that this year's Kevetrin ASCO abstract included more about the pre-clinical efficacy results; the DF team (Shapiro et al) are clearly more comfortable with standing behind that narrative, so the p21 results are likely strong. But this is what CTIX management has already said. So what we're getting at this ASCO is more confirmation than news. Confirmation is good when a management team has credibility issues. I don't think ours does, really. Certainly not more than usual for a pink-sheet.